UCB, a biopharmaceutical company, will present results from Phase 3 studies investigating the impact of bimekizumab on pain and health-related quality of life in moderate-to-severe hidradenitis suppurativa at the Symposium on Hidradenitis Suppurativa Advances. The data provide further evidence of bimekizumab’s potential to treat this chronic inflammatory condition. Despite promising results, the drug has not yet been approved by the US Food and Drug Administration.
FortiGate Firewalls Exploited in Wave of Attacks to Breach Networks and Steal Credentials
A series of intrusions in early 2026 in which threat actors compromised FortiGate Next-Generation Firewalls (NGFW) to establish persistent footholds within enterprise environments. Each case
